Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 4
2022 5
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of personalized exercise program on physical function in elderly patients with rheumatoid arthritis at high risk for sarcopenia: study protocol for a randomized controlled trial.
Onishi A, Torii M, Hidaka Y, Uozumi R, Oshima Y, Tanaka H, Onizawa H, Fujii T, Murata K, Murakami K, Tanaka M, Matsuda S, Morinobu A, Arai H, Hashimoto M. Onishi A, et al. Among authors: hidaka y. BMC Musculoskelet Disord. 2023 Apr 11;24(1):280. doi: 10.1186/s12891-023-06185-4. BMC Musculoskelet Disord. 2023. PMID: 37041556 Free PMC article.
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
Katakami N, Nishimura T, Hidaka Y, Hata A, Nishino K, Mori M, Hirashima T, Takase N, Kaneda T, Ohnishi H, Morita S, Hatachi Y. Katakami N, et al. Among authors: hidaka y. Lung Cancer. 2023 Aug;182:107261. doi: 10.1016/j.lungcan.2023.107261. Epub 2023 May 26. Lung Cancer. 2023. PMID: 37307753 Clinical Trial.
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: hidaka y. J Geriatr Oncol. 2022 Jan;13(1):88-93. doi: 10.1016/j.jgo.2021.07.002. Epub 2021 Jul 6. J Geriatr Oncol. 2022. PMID: 34238726
21 results